Xencor Regains CD20 x CD3 Bispecific T-Cell Engager
(RTTNews) - Xencor Inc. (XNCR) Thursday announced that it will regain exclusive worldwide rights to plamotamab, a CD20 x CD3 bipecific T-cell engager.
Xencor Reports First Quarter 2024 Financial Results
Xencor Appoints Bart Cornelissen as Chief Financial Officer
Xencor Inc., a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, has appointed Bart Cornelissen as senior vice president and chief financial officer.
Insider Sell: President & CEO Bassil Dahiyat Sells 12,528 Shares of Xencor
Xencor to Present at Upcoming Investor Conferences
Xencor Reports Fourth Quarter and Full Year 2023 Financial Results
Xencor to Host Webcast to Review Q4 and Full Year 2023 Financial Results
Xencor to Present at the 42nd Annual J.P. Morgan Healthcare Conference